HUE045163T2 - Új ellenanyagok foszforilkolin ellen - Google Patents

Új ellenanyagok foszforilkolin ellen

Info

Publication number
HUE045163T2
HUE045163T2 HUE12747915A HUE12747915A HUE045163T2 HU E045163 T2 HUE045163 T2 HU E045163T2 HU E12747915 A HUE12747915 A HU E12747915A HU E12747915 A HUE12747915 A HU E12747915A HU E045163 T2 HUE045163 T2 HU E045163T2
Authority
HU
Hungary
Prior art keywords
antibodies against
new antibodies
against phosphorylcholine
phosphorylcholine
new
Prior art date
Application number
HUE12747915A
Other languages
English (en)
Inventor
Knut Pettersson
Ola Camber
Dan Sexton
Andrew E Nixon
Original Assignee
Athera Biotechnologies Ab
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athera Biotechnologies Ab, Dyax Corp filed Critical Athera Biotechnologies Ab
Publication of HUE045163T2 publication Critical patent/HUE045163T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
HUE12747915A 2011-08-09 2012-08-08 Új ellenanyagok foszforilkolin ellen HUE045163T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161521593P 2011-08-09 2011-08-09

Publications (1)

Publication Number Publication Date
HUE045163T2 true HUE045163T2 (hu) 2019-12-30

Family

ID=46679261

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12747915A HUE045163T2 (hu) 2011-08-09 2012-08-08 Új ellenanyagok foszforilkolin ellen

Country Status (27)

Country Link
US (3) US9803028B2 (hu)
EP (1) EP2742068B1 (hu)
JP (1) JP6277125B2 (hu)
KR (1) KR101947758B1 (hu)
CN (1) CN104039832B (hu)
AR (1) AR087485A1 (hu)
AU (1) AU2012293646B2 (hu)
BR (1) BR112014002929A8 (hu)
CA (1) CA2843921A1 (hu)
CY (1) CY1121950T1 (hu)
DK (1) DK2742068T3 (hu)
ES (1) ES2732838T3 (hu)
HK (1) HK1200852A1 (hu)
HR (1) HRP20190988T1 (hu)
HU (1) HUE045163T2 (hu)
LT (1) LT2742068T (hu)
MX (1) MX364425B (hu)
PL (1) PL2742068T3 (hu)
PT (1) PT2742068T (hu)
RS (1) RS58986B1 (hu)
RU (1) RU2654584C2 (hu)
SG (1) SG2014009344A (hu)
SI (1) SI2742068T1 (hu)
TR (1) TR201909072T4 (hu)
TW (1) TWI707873B (hu)
WO (1) WO2013020995A1 (hu)
ZA (1) ZA201400665B (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2843960C (en) 2011-08-09 2020-09-15 Athera Biotechnologies Ab Antibodies binding to phosphorylcholine (pc) and/or pc conjugates
LT2742068T (lt) * 2011-08-09 2019-07-10 Athera Biotechnologies Ab Nauji antikūnai prieš fosforilcholiną
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
US20180066262A1 (en) 2015-03-09 2018-03-08 Caris Science, Inc. Oligonucleotide probes and uses thereof
EP3314027A4 (en) 2015-06-29 2019-07-03 Caris Science, Inc. THERAPEUTIC OLIGONUCLEOTIDES
AU2016298317B2 (en) 2015-07-28 2021-02-18 Caris Science, Inc. Targeted oligonucleotides

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2402664A1 (fr) 1977-09-07 1979-04-06 Agronomique Inst Nat Rech Produits de couplage phosphorylcholine, composes amines procede d'obtention et applications
US5955584A (en) 1986-03-31 1999-09-21 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
ATE120233T1 (de) 1986-08-06 1995-04-15 Scripps Clinic Res Monoklonale antikörper, b-spezifisch für apolipoprotein, die von zwei hybridomen erzeugt werden.
JPH02188532A (ja) 1989-01-17 1990-07-24 Otsuka Pharmaceut Co Ltd リポソームワクチン
AU5522390A (en) 1989-04-19 1990-11-16 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Process for removing c-reactive protein and anti-phosphorylcholine antibodies from biological fluids
JP3283041B2 (ja) 1990-07-13 2002-05-20 学校法人藤田学園 人工抗体
JP3183665B2 (ja) 1990-12-10 2001-07-09 エントルメド インコーポレーテッド コレステロール過剰血症およびアテローム性動脈硬化を防止するためのコレステロールに体するワクチン
RU2014609C1 (ru) * 1991-06-06 1994-06-15 Московский институт тонкой химической технологии им.М.В.Ломоносова Способ определения белков, специфичных к фосфорилхолину
JPH07504817A (ja) 1992-03-03 1995-06-01 ザ ロックフェラー ユニヴァーシティ Ｂ２９（Ｉｇ‐βまたはＩｇ−γ）を含むレセプタ複合体およびその利用
WO1994014454A1 (en) 1992-12-29 1994-07-07 Entremed, Inc. Vaccines against sterols
WO1994018955A1 (en) 1993-02-22 1994-09-01 Alza Corporation Compositions for oral delivery of active agents
US5455032A (en) 1993-07-29 1995-10-03 The United States Of America As Represented By The Department Of Health And Human Services Use of phosphocholine hapten conjugates in vaccines
US6375925B1 (en) 1996-11-08 2002-04-23 The Regents Of The University Of California Methods and reagents for non-invasive imaging of atherosclerotic plaque
WO1998021581A1 (en) 1996-11-08 1998-05-22 The Regents Of The University Of California Methods and reagents for non-invasive imaging of atherosclerotic plaque
US6225070B1 (en) 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
US20040185039A1 (en) 2002-08-30 2004-09-23 Heinz Kohler Therapeutic applications of noncovalent dimerizing antibodies
US6300308B1 (en) 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
DK1095271T3 (da) 1998-07-03 2003-12-15 Athera Biotechnologies Ab Fremgangsmåde til diagnose af hjertekar-sygdomme og tidlig aterosklerose
AU773370B2 (en) 1999-10-26 2004-05-20 Regents Of The University Of California, The Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
SE0000855D0 (sv) 2000-03-15 2000-03-15 Karolinska Innovations Ab Antigenic composition useful as a vaccine against atherosclerosis
AU2001259730A1 (en) 2000-05-12 2001-11-26 The Regents Of The University Of California Standardized oxidized ldl assay
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
SE0103754L (sv) 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
US20070122419A1 (en) 2003-04-11 2007-05-31 The Regents Of The University Of California Methods and compositions for treating atherosclerosis
AU2005233361B2 (en) 2004-04-15 2011-02-24 Athera Biotechnologies Ab Phosphorylcholine conjugates and corresponding antibodies
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
EP1868651A4 (en) * 2005-04-12 2010-10-06 Univ Duke METHOD FOR INDUCING ANTIBODIES THAT NEUTRALIZE THE HUMAN IMMUNODEFICIENCY VIRUS
WO2007076200A2 (en) 2005-11-28 2007-07-05 Medimmune, Inc. Antagonists of hmgb1 and/or rage and methods of use thereof
US20090258005A1 (en) 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
JP5122908B2 (ja) 2007-10-17 2013-01-16 日泉化学株式会社 自動車の内装用部材の取り付け構造
WO2010003602A1 (en) * 2008-07-07 2010-01-14 Athera Biotechnologies Ab New therapeutic and diagnostic methods for alzheimer's disease
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
KR102107695B1 (ko) 2011-01-06 2020-05-07 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
LT2742068T (lt) * 2011-08-09 2019-07-10 Athera Biotechnologies Ab Nauji antikūnai prieš fosforilcholiną
CA2843960C (en) 2011-08-09 2020-09-15 Athera Biotechnologies Ab Antibodies binding to phosphorylcholine (pc) and/or pc conjugates

Also Published As

Publication number Publication date
AR087485A1 (es) 2014-03-26
HK1200852A1 (en) 2015-08-14
ES2732838T3 (es) 2019-11-26
TWI707873B (zh) 2020-10-21
US20210238311A1 (en) 2021-08-05
BR112014002929A2 (pt) 2017-03-28
ZA201400665B (en) 2019-08-28
JP6277125B2 (ja) 2018-02-07
LT2742068T (lt) 2019-07-10
SG2014009344A (en) 2014-07-30
RU2654584C2 (ru) 2018-05-21
AU2012293646B2 (en) 2017-08-31
TR201909072T4 (tr) 2019-08-21
RS58986B1 (sr) 2019-08-30
KR101947758B1 (ko) 2019-02-14
PT2742068T (pt) 2019-07-08
CY1121950T1 (el) 2020-10-14
KR20140068948A (ko) 2014-06-09
TW201321415A (zh) 2013-06-01
DK2742068T3 (da) 2019-06-11
PL2742068T3 (pl) 2020-01-31
EP2742068B1 (en) 2019-04-03
AU2012293646A8 (en) 2014-03-06
AU2012293646A1 (en) 2014-02-20
BR112014002929A8 (pt) 2021-09-28
WO2013020995A1 (en) 2013-02-14
SI2742068T1 (sl) 2019-08-30
US20180086848A1 (en) 2018-03-29
CA2843921A1 (en) 2013-02-14
RU2014108815A (ru) 2015-09-20
JP2014525233A (ja) 2014-09-29
CN104039832B (zh) 2021-02-12
MX2014001313A (es) 2014-07-28
EP2742068A1 (en) 2014-06-18
MX364425B (es) 2019-04-25
CN104039832A (zh) 2014-09-10
US9803028B2 (en) 2017-10-31
HRP20190988T1 (hr) 2019-09-20
US20140178410A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
HUS2300021I1 (hu) Anti-IL-36R antitestek
HRP20180640T1 (hr) Anti-b7-h3 antitijelo
IL259826A (en) Anti-alphabetatisiar antibody
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
GB201120991D0 (en) Microsensor
TWI563004B (en) Anti-hxcr1 antibody
PL2707391T3 (pl) Przeciwciała przeciwko her3
HK1200852A1 (en) New antibodies against phosphorylcholine
EP2714074A4 (en) ANTIBODIES AGAINST EMR1
EP2769988A4 (en) ANTI-GAP43 ANTIBODY
EP2751750A4 (en) IDENTIFY THE USER TARGET RELATION
GB201116342D0 (en) Antigen combinations
GB201103827D0 (en) Biosensor